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Simple Summary: Although it is known that bacterial infection may increase risk of cancer, the
relationship between certain infections and cancer remains ill-quantified. To identify potential risk
factors, this study compared the incidence of biliary tract cancer (BTC) in patients with Salmonella
spp. or Campylobacter spp. infection to the general population in a large Western cohort of 16,252
salmonellosis and 27,668 campylobacteriosis patients. Standardized relative incidence ratio for BTC
was 1.53 (95% CI 0.70–2.91) in salmonellosis patients and 0.97 (95% CI 0.39–2.00) in campylobacteriosis
patients. Patients with Salmonella spp. infection and BTC were significantly younger than BTC patients
without Salmonella spp. infection. Potentially, the study was underpowered to detect differences in
cancer incidence, or cancer etiology in Western patients differs from those in non-Western countries
and instead of bacterial infection, other factors contribute to cancer risk. Better understanding
of cancer etiology is needed to identify risk factors and facilitate screening and early detection of
cancer patients.
Abstract: Salmonella spp. infection has shown to have oncogenic transformative effects and thereby
increases the risk of certain cancers. For Campylobacter spp., similar effects have been demonstrated.
Risk factor identification may allow for timely diagnosis and preventive treatment. To substantiate
the oncogenic potential of Salmonella and Campylobacter spp., this study compared the incidence of
extrahepatic biliary tract cancer (BTC) in patients with diagnosed Salmonella or Campylobacter spp.
infection with BTC incidence in the Netherlands. National infectious diseases surveillance records of
patients diagnosed with a laboratory-confirmed Salmonella or Campylobacter spp. infection during
1999–2016 were linked to the Netherlands Cancer Registry. Incidence of BTC in Salmonella and
Campylobacter spp. patients was compared to the incidence of BTC in the general population using
Standardized Incidence Ratios (SIRs). In total, 16,252 patients were diagnosed with Salmonella spp.
and 27,668 with Campylobacter spp. infection. Nine patients developed BTC at a median of 46 months
(13–67) after Salmonella spp. infection and seven at a median of 60 months (18–138) after Campylobacter
spp. infection. SIR of BTC in salmonellosis patients was 1.53 (95% CI 0.70–2.91). In patients aged
<60 years, the SIR was 1.74 (95% CI 0.36–5.04). For campylobacteriosis patients, the SIR was 0.97 (95%
CI 0.39–2.00). Even though Salmonella or Campylobacter spp. infection was not significantly associated
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with increased BTC risk in this cohort, it remains extremely important to study potential risk factors
for cancer to facilitate screening and ultimately improve prognosis of cancer patients.
Keywords: bacterial infection; cancer; epidemiology; risk factor
1. Introduction
Biliary tract cancers (BTC) are rare malignancies of the distal and proximal bile ducts, the
gallbladder and the cystic duct. Despite significant improvement in the overall survival of cancer
patients, 5-year survival of patients with extrahepatic biliary tract cancer (i.e., gallbladder cancer,
proximal and distal cholangiocarcinoma) is still only 10% [1–3]. Currently, radical surgery is the
only curative treatment available. Unfortunately, surgery is not an option in the majority of patients,
because BTC frequently goes undetected until the disease has progressed to an advanced, unresectable
stage [4,5].
Geography appears to be the primary risk factor for the development of non-intrahepatic BTC,
and as a result, incidence rates vary significantly per region. For example, gallbladder cancer (GBC)
incidence ranges from 0.9/100,000 women in the Netherlands to 35/100,000 women in Chile [6,7]. Other
risk factors for BTC include age, parasitic infections, congenital malformations of the biliary tract and
primary sclerosing cholangitis, and sex [8]. However, most patients with BTC do not have any of
the known risk factors apart from age [9]. Screening for and detection of risk factors in addition to
geography and age could lead to significantly faster detection of BTC and a subsequent improvement
in survival.
An estimated 20% of the global cancer burden can be attributed to infectious diseases [10]. The
association between viral infections, such as human papilloma virus, hepatitis B and C and certain
forms of cancer, has been well-established [11,12]. This knowledge has led to the implementation of
successful targeted treatment and screening programs that can facilitate prevention and early detection
of these cancers and improve survival, such as the Dutch national program for cervical cancer [13].
Although less studied, bacteria also have oncogenic potential and thereby increase the risk of cancer [14].
The primary example is Helicobacter pylori infection, which increases the risk of gastric cancer through
the secretion of toxins that mediate cell signaling, as well as chronic inflammation [15]. Similarly,
Salmonella spp. enforce bacterial uptake by manipulating host cell signaling pathways. Specifically,
host AKT and ERK pathways are activated. Both pathways are active in many cancers and are an
essential step in the malignant transformation of pre-transformed cells [16]. Salmonella spp. infection
is common and represents a known risk factor for gallbladder and colon cancers, with the former
pertaining specifically to Salmonella typhi, the agent of typhoid fever, and the latter to non-typhoidal
Salmonellae [16,17]. However, the role of non-typhoidal Salmonella has not yet been investigated for other
biliary cancers. Campylobacter spp. is another frequently-occurring gastrointestinal infection able to
promote colon tumorigenesis by producing cytolethal distending toxins and is more frequently present
in the microbiome of colorectal cancer patients, although a causal relationship between colorectal
cancer and Campylobacter spp. infection has not been demonstrated [18–21].
Salmonella spp. is known to cause chronic inflammation of the bile ducts and to produce toxins
with carcinogenic potential, which may lead to cancer of the extrahepatic biliary tract [22]. After an
outbreak of Salmonella typhi in 1964, researchers found that the risk of biliary tract cancer was increased
by 164 times in carriers compared to non-carriers [23]. Although non-typhoidal Salmonella has been
associated with the development of colon cancer, its role has not been specifically investigated in biliary
tract cancers other than gallbladder cancer [17]. Campylobacter spp. is found in abundance in the biliary
microbiome of patients with BTC [24]. The potential association with non-typhoidal Salmonella or
Campylobacter spp. and BTC has not been studied in large cohorts due to the rarity of BTC, especially
in Western populations. In case an association is found, targeted screening for BTC in Salmonella spp.
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and Campylobacter spp. patients might be considered. To assess whether infection with non-typhoidal
Salmonella or Campylobacter spp. is a risk factor for BTC, this study compares the incidence of BTC in
patients with a registered non-typhoidal Salmonella or Campylobacter spp. infection in the past to the
incidence of BTC in a Western–European population.
2. Results
2.1. Cohort Characteristics
The final cohort consisted of 16,283 Salmonella spp. patients (reported between 1999–2016), 27,692
Campylobacter spp. patients (reported between 2002–2016) and 8506 patients with BTC (Figure 1). After
linkage, nine Salmonella spp. patients and seven Campylobacter spp. patients were diagnosed with BTC
≥1 year after infection.
Figure 1. Cohort selection. ehBTC = extrahepatic biliary tract cancer.
Baseline characteristics of the cohorts are provided in Table 1 (Salmonellosis and Campylobacteriosis)
and Table 2 (BTC). Median age at infection was 48.9 years (IQR: 30.0–66.0) for salmonellosis patients
(66.5%, <60 years) and 48.5 years (IQR: 31.3–62.4) for campylobacterosis patients (70.8%, <60 years).
Median follow-up after infection was 7 years (IQR 3–12) in salmonellosis patients and 5 years (IQR 3–9) in
campylobacterosis patients. Median age at diagnosis was 73 years (IQR 64–80) in BTC patients. Median
follow-up time from diagnosis to death or end of study in in BTC patients was 55 months.
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Table 1. Baseline characteristics of the Salmonellosis and Campylobacterosis patients.













Typhimurium/monophasic var. 4487 (28%)
Enteritidis 5544 (34%)
(Para)Typhi 318 (2%)

















C. jejuni 23,647 (85%)
C. coli 1910 (7%)





1 Not registered for campylobacterosis cases.
Table 2. Baseline characteristics of patients with BTC in the Netherlands (2000–2017).











Cancers 2020, 12, 3348 5 of 12
Table 2. Cont.
Characteristic N (%)/Median (95% CI)
Tumor location
Gallbladder 2586 (30%)
Bile ducts, NOS 2421 (28%)
Proximal bile ducts 1846 (22%)
Distal bile ducts 1490 (18%)







Survival (months) 5.8 (5.5–6.0)
1 Includes cystic duct and mixed types.
2.2. Patients with Salmonella spp. Infection and BTC
Nine salmonellosis patients were diagnosed with BTC ≥1 year after salmonellosis diagnosis
(Table 3). Mean time to BTC diagnosis was 47 months (range 13–81). Three of nine (33%) salmonellosis
patients were ≤50 years old at time of BTC diagnosis, as opposed to the general BTC population, in
which only 5.0% of patients were ≤50 years old at time of BTC diagnosis (p < 0.001). Four cases were
diagnosed with S. enteritidis, three with S. typhimurium, and two with other Salmonella serovars. Eight
patients had an enteric infection, one had an invasive (bloodstream) infection. Two patients had a distal
cholangiocarcinoma, one patient had a proximal cholangiocarcinoma, one patient had gallbladder
cancer, and five had BTC NOS (not otherwise specified).
Table 3. Baseline characteristics of patients with Salmonella spp. infection and biliary tract cancer.
Characteristic N (%)






Typhimurium/monophasic var. 2 (22%)
Other 3 (33%)
Interval
<60 months 7 (78%)
≥60 months 2 (22%)
Tumor location
Gallbladder/proximal bile ducts 2 (22%)
Distal bile ducts 2 (22%)
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2.3. Patients with Campylobacter spp. Infection and BTC
Seven campylobacteriosis patients were diagnosed with BTC ≥1 year after diagnosis (Table 4).
Mean time to BTC diagnosis was 60.6 months (range 18–138). All patients were >50 years of age
at time of BTC diagnosis. Five patients had a proximal cholangiocarcinoma and two patients had
gallbladder cancer.
Table 4. Baseline characteristics of patients with Campylobacter spp. infection and biliary tract cancer.
Characteristic N (%)





<60 months 3 (43%)
≥60 months 4 (57%)
Tumor location
Gallbladder/proximal bile ducts 1
Distal bile ducts 1




1 Numbers cannot be provided due to risk of subject identification.
2.4. Risk of BTC After Salmonella spp. or Campylobacter spp. Infection
The SIR of BTC among the salmonellosis patients (compared to the general population) was 1.53
(95% CI 0.70–2.91, Table 5) and the absolute risk was 0.05%. Subgroup analysis in patients <60 years of
age demonstrated that the SIR in this group was 1.72 (CI 0.36–5.04). Subgroup analysis according to
gender revealed similar findings. In campylobacteriosis patients, the SIR was 0.97 (95% CI 0.39–2.00,
Table 5) and the absolute risk was 0.03%. Subgroup analyses stratified according to gender and age
revealed similar results.
Table 5. Incidence of biliary tract cancer in patients ≥1 year after laboratory-confirmed infection with
Salmonella spp. or Campylobacter spp., stratified by age at infection and gender.
Type ObservedIncidence
Expected
Incidence SIR 95% CI p-Value
Salmonella spp.
All patients 9 5.875 1.53 0.70–2.91 0.280
20–60 3 1.740 1.72 0.36–5.04 0.507
Male 5 2.665 1.88 0.61–4.38 0.264
Female 4 3.289 1.22 0.33–3.11 0.835
Campylobacter spp.
All patients 7 7.221 0.97 0.39–2.00 0.868
20–60 2 2.126 0.94 0.11–3.40 0.715
Male 3 4.025 0.75 0.15–2.18 0.857
Female 4 3.233 1.24 0.34–3.17 0.810
3. Discussion
This study assessed whether Salmonella spp. or Campylobacter spp. infection represents a significant
risk factor for BTC by comparing the incidence of BTC in patients with a history of Salmonella spp.
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or Campylobacter spp. infection to the (age-, gender- and calendar year-matched) incidence of BTC
in the general Dutch population. Additionally, age and gender effects on the association between
Salmonella spp. or Campylobacter spp. infection and BTC were investigated. No significant increase
in BTC occurrence in patients who had experienced a severe Salmonella spp. or Campylobacter spp.
infection was observed.
The relatively low number of Salmonella spp. (and Campylobacter spp.) infections linked to the
(already rare) BTC patients found in this study was the main limitation for statistical significance, as
considerable uncertainty was introduced in the estimates by such low number of outcome events.
The upper limit of the SIR for BTC in salmonellosis patients was 2.7, which implies that a clinically
significant effect may be present, but the study is simply insufficiently powered to detect its presence.
This issue is, however, not unique to this study alone, but rather affects all studies investigating rare
diseases. Experts increasingly recognize that some evidence, although maybe imprecise, may be better
than no evidence at all [25].
In countries where typhoid fever is still endemic, such as the Indian subcontinent and some parts
of South America, multiple epidemiological studies have shown an increased risk for the development
of BTC and especially gallbladder cancer. Besides chronic infection, an increased risk of gallstones
in these populations, a higher incidence of obesity, and potential environmental pollution have been
mentioned as potentially contributing to this phenomenon [22]. However, none of these factors (apart
from gallstones and gallbladder cancer, which is not unique to these countries) show an extremely
high correlation with the incidence of BTC. On the other hand, researchers have demonstrated a
clear association with chronic S. typhi infection and the development of gallbladder cancer in these
countries [26]. In contrast, a Chinese study investigating the correlation between chronic infection
with S. typhi and biliary tract cancer failed to find a significant association due to a very low occurrence
of such infection [27]. One may argue that association does not equal causation and that in areas with
endemic typhoid fever and high rates of gallbladder cancer, other factors might be at play as well.
However, even in Western countries with typically extremely low incidence of S. typhi infection (as
typhoid fever has been eradicated in most Western countries thanks to modern sanitation), after large
outbreaks of typhoid fever, an increase in number of BTC diagnoses was observed [23].
This paper focusses primarily on the incidence of BTC in non-typhoidal Salmonella. We
hypothesized that, similar to gallbladder cancer, the increased incidence of BTC after typhoidal
Salmonella infection would translate to increased BTC risk in non-typhoidal Salmonella [28]. The lack of
significant correlation in non-typhoid Salmonella infection may be attributed to the fact that non-typhoid
Salmonella strains are less likely to cause chronic infection and thus have lower oncogenic potential
compared to their typhoid counterparts [29].
Remarkably, one third of the patients with both Salmonella spp. infection and BTC were under
50 years of age at time of BTC diagnosis. This proportion was significantly higher than in the general
BTC population, in which only 5% is aged 50 years or younger [30]. Because the risk of BTC increases
exponentially with age, we performed a subgroup analysis in all patients aged <60. Although this
subgroup analysis also failed to reach significance due to the even lower numbers, the relatively
high proportion of young patients suggests that Salmonella spp. infection at a young age might
contribute to the risk of developing BTC later in life. Possibly, patients who acquire a Salmonella
spp. infection at the age of 70 or older may die from other diseases before they develop BTC and are
thus less well-represented. The median time between Salmonella spp. infection and BTC diagnosis
was 4 years. This finding implies that the potential oncogenic effect of Salmonella spp. results in
malignant transformation of epithelial cells in a relatively short timeframe and is concurrent with other
studies [17]. Another explanation may be that patients with inflammatory bowel disease (IBD) are at a
higher risk for developing a serious Salmonella spp. infection. Since IBD often has an onset in early
adulthood and is also a potential independent risk factor for the development of BTC, it is possible
that this difference in age can be explained by the fact that the patients with Salmonella spp. infection
also had IBD and therefore were at greater risk for developing BTC at a younger age [31].
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No tendency towards increased BTC incidence after Campylobacter spp. infection was seen in this
study. Campylobacter spp. and Salmonella spp. bacteria both release the genotoxic protein cytolethal
distending toxin (CDT). However, whereas Salmonella spp. is linked to the development of BTC by
overexpression of C-myc in tissue samples, Campylobacter spp. is not [16]. Differences in bacterial
mechanisms, specifically concerning the alteration of host cell signaling pathways during invasion,
may account for differences in oncogenic potential between the two species.
Molecular characterization of cancers and subsequent personalization of therapy is a prime topic
in current oncological research. Although the genomic landscape of BTC is incredibly diverse, multiple
preclinical and clinical models show that BTC development may be associated with the alteration of
several actionable genes. A particular example is the overexpression of cyclophilin-A in patients with
liver-fluke-associated cholangiocarcinoma [32,33]. Identification of inflammation-associated driving
mutations is an important topic as it has implications for both risk profiling and potential personalized
treatment. Although molecular profiling of patients with salmonellosis and BTC was outside of the
scope of this study, a study in gallbladder cancer has managed to identify the signaling pathway
associated with S. typhi development and gallbladder cancer [16]. Further research investigating
molecular alterations in infected cancer patients is paramount to increase our understanding of tumor
cell transformation and cancer development.
The primary limitation of this study is the low number of Salmonella spp. and Campylobacter spp.
infected patients that also developed BTC, leading to a high risk of type-2 error. Typically, patients
with Salmonella spp. infection in the Netherlands who require medical attention, laboratory diagnosis
and reporting to health authorities are severely ill. As most patients with Salmonella spp. infection
only show mild symptoms, the actual number of Salmonella spp. cases in the Netherlands is much
higher than reported. It is estimated that close to 1 million inhabitants developed a symptomatic
Salmonella spp. infection in the Netherlands between 1999–2015, which is 35 times the number of
cases included in this study. Campylobacteriosis cases are estimated around 81,000 in the Netherlands
annually [34]. As a result, a number of patients with mild and therefore unreported Salmonella spp. or
Campylobacter spp. infection, but with a BTC diagnosis, may have been misclassified and included in
the group of BTC patients without (reported) Salmonella spp. or Campylobacter spp. infection. Since
the contribution of these mild infections to the risk of developing BTC is implicitly included in the
baseline risk, our results may be considered as very conservative estimates of their true contribution to
BTC risk. Moreover, although chronic infections are those mostly implicated in BTC formation, they
could not be studied as such in this study because this information (i.e., differentiation between acute
and chronic infection) is simply not available in the RIVM data set [35]. Yet, we included all reported
infections, and because these infections represent the most severe ones (in terms of magnitude and
duration of symptoms) occurring in the population, our analysis implicitly focused on a selection of
salmonellosis and campylobacteriosis patients that showed extreme clinical manifestations. Finally,
the RIVM registry only contains data on Salmonella spp. and Campylobacter spp. infection from 1999
onwards and consequently we only had a median follow-up period of 7 years. If, like in pancreatic
cancer, the interval between first mutation and cancer development is over 10 years, the study period
may have been insufficient to detect a correlation between infection and BTC development [36].
A major strength of this study is the cohort size and nation-wide design. Indeed, it should be
acknowledged that the low number of BTC events in our cohort—despite the large surveillance data
sets used—reflects mainly the rare occurrence of these tumors. The cohort analyzed in this paper
is large and comprehensive, being nation-wide and covering all available years of systematic data
collection. Previous studies investigating the role of bacterial infections in the development of BTC
have typically drawn from case-control cohorts or small case series. Additionally, to our knowledge,
this paper describes the first Western cohort of patients with Salmonella spp. or Campylobacter spp.
infection and BTC [26].
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4. Materials and Methods
4.1. Data Collection and Linkage
Analyses were based on three linked health registries with national coverage. The first registry
contains records from laboratory-confirmed human infections with Salmonella spp. (from 1999 onwards)
and Campylobacter spp. (from 2002 onwards) based on the national laboratory surveillance system
for gastrointestinal pathogens coordinated by the Dutch National Institute for Public Health and the
Environment (RIVM) [35]. The surveillance system has an estimated coverage of the resident Dutch
population of 64% for Salmonella spp. and 52% for Campylobacter spp. infection [37]. The second
registry consisted of histopathological records provided by the automated pathological archive, the
nation-wide network of histopathology and cytology in the Netherlands (PALGA) [38]. The third
registry was the Netherlands Cancer Registry (NCR) [39], which contains data on all newly diagnosed
malignancies since 1989, covering around 95% of the Dutch population [39]. The NCR is updated
through PALGA and supplemented annually by information from hospital discharge records. Statistics
Netherlands (CBS, www.cbs.nl)acted as a trusted third party to anonymize and link the data sets. The
CBS used the date of birth, gender and six digit postal code, which were available in all three registries,
to generate a unique personal identifier (Record Identification Number (RIN)). After the RIN was
generated, all personally identifying data was removed from the data sets. The researchers used the
RIN to link all three data sets. Ethical Approvals were given by the CMO Arnhem-Nijmegen, code:
2017-3912 in 18 December 2017. A waiver of informed consent was provided, no informed consent
form was used.
4.2. Patient Selection and Variable Definitions
All patients aged ≥20 years of age with a diagnosed non-typhoidal Salmonella infection from
the 1 January 1999, and with a diagnosed Campylobacter spp. infection from the 1 January 2002,
until the 31 December 2016 were identified in the RIVM database. Additionally, all patients with
non-intrahepatic biliary tract cancer (ICD-O-3 location codes C239, C240, C242, C243, C244, C248, C249)
were identified in the NCR database. Patients who were diagnosed with intrahepatic BTC, BTC before
or within 1 year of salmonellosis/campylobacteriosis diagnosis or had less than 1 year of follow-up
were excluded. In case the patient had multiple recorded Salmonella spp./Campylobacter spp. infections,
only the first diagnosis was considered. Both databases were cleared from duplicates. Time at risk was
defined as the number of days between 1 year after salmonellosis/campylobacteriosis diagnosis and
development of BTC, death, or end of the study period (31 December 2017), whichever occurred first.
4.3. Outcomes
The primary outcome of the study was the incidence of BTC among individuals with a registered
non-typhoidal Salmonella or Campylobacter spp. infection in the past as compared to the incidence of
BTC in the general Dutch population. Subgroup analyses were conducted to investigate the risk of
BTC in patients ≤60 years of age (at the time of infection) and by gender.
4.4. Statistical Analysis
Standardized incidence ratios (SIR) were calculated for salmonellosis and campylobacteriosis
patients separately to compare the difference in incidence of BTC in patients with Salmonella spp. or
Campylobacter spp. infection to an age-, gender- and calendar year-matched cohort of the general Dutch
population. To this end, the observed number of BTC cases in the salmonellosis and campylobacteriosis
patients was divided by the expected number of BTC cases in the matched cohort provided by the NCR.
95% confidence intervals (95% CI) for the SIRs were calculated assuming a Poisson distribution. In all
analyses, p-values < 0.05 were considered statistically significant. Statistical analysis was performed
using STATA version 14 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX:
StataCorp LP).
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5. Conclusions
There is accumulating evidence that pathogenic bacteria like Salmonella spp. play a role in cancer
development, including cancers of the digestive system. However, we could not demonstrate a
significantly increased occurrence of BTC among reported salmonellosis or campylobacteriosis patients
as compared to the general population. Potentially, the study was either underpowered due to the
low number of BTC events or Salmonella and Campylobacter spp. infections are not associated with the
development of BTC in Western countries. Additional research is needed to unravel the biological
mechanisms behind bacterial infections as a cause of cancer and identify potential infections that
may warrant early screening and therefore facilitate early cancer detection, especially in third-world
countries with high rates of (hyper)endemic bacterial infections.
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